Teduglutide Reduced Parenteral Support in Children with Short Bowel Syndrome Associated-Intestinal Failure (SBS–IF): A Phase 3 Study

Rationale: A 12-wk, open-label study demonstrated the safety and efficacy of teduglutide (TED) treatment in children with SBS‒IF.1 This 24 wk, phase 3 study (NCT02682381; EudraCT 2015-002252-27) assessed the safety and efficacy of 0.025 and 0.05 mg/kg TED in children with SBS‒IF.